Health Policy and Management (보건행정학회지)

Korean Academy of Health Policy and Management (한국보건행정학회)
권호 표지
DOI QR코드

DOI QR Code

Cost-Effectiveness Analysis for National Dyslipidemia Screening Program in Korea: Results of Best Case Scenario Analysis Using a Markov Model

  • Kim, Jae-Hyun (Department of Health Administration, Dankook University College of Health Science) ;
  • Park, Eun-Cheol (Department of Preventive Medicine, Yonsei University College of Medicine) ;
  • Kim, Tae-Hyun (Institute of Health Services Research, Yonsei University) ;
  • Nam, Chung-Mo (Department of Preventive Medicine, Yonsei University College of Medicine) ;
  • Chun, Sung-Youn (Institute of Health Services Research, Yonsei University) ;
  • Lee, Tae-Hoon (Institute of Health Services Research, Yonsei University) ;
  • Park, Sohee (Institute of Health Services Research, Yonsei University)
  • Received : 2019.03.27
  • Accepted : 2019.08.28
  • Published : 2019.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: This study evaluated the cost-effectiveness of 21 different national dyslipidemia screening strategies according to total cholesterol (TC) cutoff and screening interval among 40 years or more for the primary prevention of coronary heart disease over a lifetime in Korea, from a societal perspective. Methods: A decision tree was used to estimate disease detection with the 21 different screening strategies, while a Markov model was used to model disease progression until death, quality-adjusted life years (QALYs) and costs from a Korea societal perspective. Results: The results showed that the strategy with TC 200 mg/dL and 4-year interval cost \4,625,446 for 16.65105 QALYs per person and strategy with TC 200 mg/dL and 3-year interval cost \4,691,771 for 16.65164 QALYs compared with \3,061,371 for 16.59877 QALYs for strategy with no screening. The incremental cost-effectiveness ratio of strategy with TC 200 mg/dL and 4-year interval versus strategy with no screening was \29,916,271/QALY. At a Korea willingness-to-pay threshold of \30,500,000/QALY, strategy with TC 200 mg/dL and 4-year interval is cost-effective compared with strategy with no screening. Sensitivity analyses showed that results were robust to reasonable variations in model parameters. Conclusion: In this study, revised national dyslipidemia screening strategy with TC 200 mg/dL and 4-year interval could be a cost-effective option. A better understanding of the Korean dyslipidemia population may be necessary to aid in future efforts to improve dyslipidemia diagnosis and management.

Keywords

References

  1. Li YH, Li Y, Davis CE, Chen Z, Tao S, Folsom AR, et al. Serum cholesterol changes from 1983-1984 to 1993-1994 in the People’s Republic of China. Nutr Metab Cardiovasc Dis 2002;12(3):118-126.
  2. Sekikawa A, Kuller LH, Ueshima H, Park JE, Suh I, Jee SH, et al. Coronary heart disease mortality trends in men in the post World War II birth cohorts aged 35-44 in Japan, South Korea and Taiwan compared with the United States. Int J Epidemiol 1999;28(6):1044-1049. DOI: https://doi.org/10.1093/ije/28.6.1044.
  3. Roh E, Ko SH, Kwon HS, Kim NH, Kim JH, Kim CS, et al. Prevalence and management of dyslipidemia in Korea: Korea National Health and Nutrition Examination Survey during 1998 to 2010. Diabetes Metab J 2013;37(6):433-449. DOI: https://doi.org/10.4093/dmj.2013.37.6.433.
  4. Jee SH, Jang Y, Oh DJ, Oh BH, Lee SH, Park SW, et al. A coronary heart disease prediction model: the Korean Heart Study. BMJ Open 2014;4(5):e005025. DOI: https://doi.org/10.1136/bmjopen-2014-005025.
  5. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011;123(8):933-944. DOI: https://doi.org/10.1161/CIR.0b013e31820a55f5.
  6. Chang HS, Kim HJ, Nam CM, Lim SJ, Jang YH, Kim S, et al. The socioeconomic burden of coronary heart disease in Korea. J Prev Med Public Health 2012;45(5):291-300. DOI: https://doi.org/10.3961/jpmph.2012.45.5.291.
  7. Statistics Korea. Annual report on the cause of death statistics. Daejeon: Statistics Korea; 2011.
  8. Kong MH, Fonarow GC, Peterson ED, Curtis AB, Hernandez AF, Sanders GD, et al. Systematic review of the incidence of sudden cardiac death in the United States. J Am Coll Cardiol 2011;57(7):794-801. DOI: https://doi.org/10.1016/j.jacc.2010.09.064.
  9. Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006;26(4):410-420. DOI: https://doi.org/10.1177/0272989x06290495.
  10. Eaton CB. Hyperlipidemia. Prim Care 2005;32(4):1027-1055. DOI: https://doi.org/10.1016/j.pop.2005.09.002.
  11. Liu JL, Maniadakis N, Gray A, Rayner M. The economic burden of coronary heart disease in the UK. Heart 2002;88(6):597-603. DOI: https://doi.org/10.1136/heart.88.6.597.
  12. Kim SY, Han JY, Kim YJ, Sung JD, Chae IH, Kim HS, et al. Long term survival rate and prognositc factors of acute myocardial infarction. Korean Circ J 1999;29(1):14-21. https://doi.org/10.4070/kcj.1999.29.1.14
  13. Statistic Korea. Korea vital statistics data. Daejeon: Statistics Korea;2012.
  14. National Health Insurance Service. National health screening statistical yearbook. Wonju: National Health Insurance Service; 2012.
  15. Ministry of Health and Welfare. Korea health statistics 2012. Sejong: Ministry of Health and Welfare; 2012.
  16. Langsted A, Freiberg JJ, Tybjaerg-Hansen A, Schnohr P, Jensen GB, Nordestgaard BG. Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. J Intern Med 2011;270(1):65-75. DOI: https://doi.org/10.1111/j.1365-2796.2010.02333.x.
  17. U.S. Department of Health and Human Services. Screening for lipid disorders. Rockville (MD): Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services; 2001.
  18. Ray JG, Norris CM, Udell JA, Tsuyuki RT, McAlister FA, Knudtson ML, et al. Lipid-lowering therapy and outcomes in heart failure. J Cardiovasc Pharmacol Ther 2007;12(1):27-35. DOI: https://doi.org/10.1177/1074248407299839.
  19. National Health Insurance Service. National Health Screening Examination. Wonju: National Health Insurance Service; 2009.
  20. Briggs AH, Claxton K, Sculpher MJ. Decision modeling for health economic evaluation. Oxford: Oxford University Press; 2006.
  21. Korea Centers for Disease Control and Prevention. Cost-effectiveness analysis of mass screening for type 2 diabetes mellitus. Cheongju: Korea Centers for Disease Control and Prevention; 2013.
  22. Lalonde L, Clarke AE, Joseph L, Mackenzie T, Grover SA; Canadian Collaborative Cardiac Assessment Group. Health-related quality of life with coronary heart disease prevention and treatment. J Clin Epidemiol 2001;54(10):1011-1018. DOI: https://doi.org/10.1016/s0895-4356(01)00361-4.
  23. Ministry of Health and Welfare. Health insurance medical costs. Sejong: Ministry of Health and Welfare; 2014.
  24. Korea Centers for Disease Control and Prevention. Korea National Health and Nutrition Examination Survey. Cheongju: Korea Centers for Disease Control and Prevention; 2005.
  25. Korea Institute for Health and Social Affairs. Korea Health Panel. Sejong: Korea Institute for Health and Social Affairs; 2008.
  26. Goldman L, Garber AM, Grover SA, Hlatky MA. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events: task force 6: cost effectiveness of assessment and management of risk factors. J Am Coll Cardiol 1996;27(5):1020-1030. DOI: https://doi.org/10.1016/0735-1097(96)87734-5.
  27. Goldman L, Goldman PA, Williams LW, Weinstein MC. Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications. Am J Cardiol 1993;72(10):75D-79D. DOI: https://doi.org/10.1016/0002-9149(93) 90015-5.
  28. Unwin N, Thomson R, O'Byrne AM, Laker M, Armstrong H. Implications of applying widely accepted cholesterol screening and management guidelines to a British adult population: cross sectional study of cardiovascular disease and risk factors. BMJ 1998;317(7166):1125-1130. DOI: https://doi.org/10.1136/bmj.317.7166.1125.
  29. Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med 2000;132(10):769-779. DOI: https://doi.org/10.7326/0003-4819-132-10-200005160-00002.
  30. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 1991;265(9):1145-1151. DOI: https://doi.org/10.1001/jama.265.9. 1145.